Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07221149 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
A Phase 2 study of Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 690
- Enrollment target
- 20
- Study locations
NCT07221149 is a Phase 2 study of Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 690 participants. The trial reports 20 study locations across 13 states.
The verdict
NCT07221149, a Phase 2 study of Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 690 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of Pumitamig in combination with chemotherapy versus Nivolumab in combination with chemotherapy in participants with previously untreated advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Pumitamig
- DRUG Folfox
- DRUG Capox
Study Locations (20)
Florida
- Florida Cancer Specialists - South - Fort Myers
- Local Institution - 0433 - Jacksonville
- Florida Cancer Specialists - North - St. Petersburg
- Local Institution - 0246 - Tampa
California
- Local Institution - 0437 - Los Angeles
- Local Institution - 0277 - Orange
- Local Institution - 0428 - San Francisco
New York
- Local Institution - 0386 - Lake Success
- Local Institution - 0242 - New York
- Local Institution - 0274 - Rochester
Arizona
- Local Institution - 0284 - Phoenix
Georgia
- Local Institution - 0377 - Atlanta
Illinois
- Local Institution - 0379 - Chicago
Iowa
- Local Institution - 0268 - Iowa City
Minnesota
- Local Institution - 0259 - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 690 participants |
| Start Date | 2026-03-31 |
| Est. Completion | 2032-09-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07221149
The ClinicalTrials.gov registry entry for NCT07221149 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 690 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma appearing as the primary indexed condition, and to 4 interventions - of which Nivolumab is the first listed.
NCT07221149 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, California, New York.
Frequently Asked Questions
What is clinical trial NCT07221149 about?
NCT07221149 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)". The purpose of this study is to evaluate the safety and efficacy of Pumitamig in combination with chemotherapy versus Nivolumab in combination with chemotherapy in participants with previously untreated advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma
What is the current status of trial NCT07221149?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 690 participants. The study started on 2026-03-31. Estimated completion is 2032-09-11.
What conditions does trial NCT07221149 study?
This clinical trial studies the following conditions: Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma.
What interventions are being tested in trial NCT07221149?
The interventions under investigation include: Nivolumab (DRUG), Pumitamig (DRUG), Folfox (DRUG), Capox (DRUG).
Who is sponsoring clinical trial NCT07221149?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07221149 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.